{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:34Z","timestamp":1787161294237,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T00:00:00Z","timestamp":1570924800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2019,10,13]]},"abstract":"\n Aim<\/jats:italic>\n . To evaluate the diagnosis value of serum human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the Risk of Ovarian Malignancy Algorithm (ROMA), and Copenhagen Index (CPH-I) at early stages for differentiating borderline ovarian tumors from epithelial ovarian cancer.\n Methods<\/jats:italic>\n . We recruited 144 borderline ovarian tumors in FIGO stages I and II (BOT I+II), 108 epithelial ovarian cancers in FIGO stages I and II (EOC I+II), and 238 benign ovarian tumor patients with surgical treatment in the retrospective study. The concentration of HE4 and CA125 and the values of CPH-I and ROMA were assessed separately.\n Results<\/jats:italic>\n . The HE4 level and ROMA and CPH-I values of EOC I+II were all higher than that of BOT I+II and benign groups whether in all, pre-, or postmenopausal groups (\n \n P<\/mml:mi>\n <<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:math>\n ). When distinguishing BOT I+II from EOC I+II, the AUC-ROC of CPH-I and HE4 were bigger than CA125 (\n \n P<\/mml:mi>\n <<\/mml:mo>\n 0.001<\/mml:mn>\n <\/mml:math>\n ), while the CPH-I has the highest sensitivities in all and postmenopausal groups (78.7%, 85.1%), and HE4 has the highest specificity and PPV (90.91%, 88.64%) in postmenopausal groups. Under pathological stratification, HE4, ROMA, and CPH-I of the serous EOC I+II were higher than that of BOT I+II (\n \n P<\/mml:mi>\n <<\/mml:mo>\n 0.001<\/mml:mn>\n <\/mml:math>\n ) and the AUC of the three indices were significantly bigger than CA125 (\n \n P<\/mml:mi>\n <<\/mml:mo>\n 0.001<\/mml:mn>\n <\/mml:math>\n ). However, the concentration of HE4 and CA125 and the values of CPH-I and ROMA have no significant difference between the two endometrioid subgroups. The index with the highest sensitivity and NPV among the four indices of different pathological subtype groups was CPH-I, and the index with the highest specificities and PPV was HE4.\n Conclusion<\/jats:italic>\n . CPH-I was more valuable than CA125 for differentiating BOT I+II from EOC I+II regardless of menopausal status, while HE4 might be better than CA125 for postmenopausal subgroups. HE4 and CPH-I were more favorable than CA125 for differentiating BOT I+II from EOC I+II in the case of unknown pathology or in serous type.\n <\/jats:p>","DOI":"10.1155\/2019\/6241743","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T19:33:02Z","timestamp":1570995182000},"page":"1-10","source":"Crossref","is-referenced-by-count":13,"title":["CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages"],"prefix":"10.1155","volume":"2019","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5564","authenticated-orcid":true,"given":"Zhiheng","family":"Wang","sequence":"first","affiliation":[{"name":"Obstetrics and Gynecology Hospital of Fudan University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-118X","authenticated-orcid":true,"given":"Xiang","family":"Tao","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Hospital of Fudan University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0834","authenticated-orcid":true,"given":"Chunmei","family":"Ying","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Hospital of Fudan University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000048"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2017.04.001"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-001-0052-2"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-016-2040-8"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.06.010"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw090"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1002\/uog.7334"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1002\/uog.4002"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0163-z"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.7150\/thno.26345"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/803598"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2009.20.3.176"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S155693"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5289804"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12371"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.025"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.06.021"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2014.02.004"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.023"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.06.001"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1515\/med-2016-0024"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.031"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.03.043"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5058"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.07.106"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2015.09.008"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30676"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11345"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.05.013"},{"issue":"2","key":"30","first-page":"166","volume":"30","year":"2016","journal-title":"Oncology"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2019\/6241743.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2019\/6241743.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2019\/6241743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T19:33:09Z","timestamp":1570995189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/dm\/2019\/6241743\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,13]]},"references-count":30,"alternative-id":["6241743","6241743"],"URL":"https:\/\/doi.org\/10.1155\/2019\/6241743","relation":{},"ISSN":["0278-0240","1875-8630"],"issn-type":[{"value":"0278-0240","type":"print"},{"value":"1875-8630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,13]]}}}